Back close

The utility of serum amylase as a prognostic marker in multiple myeloma

Publication Type : Scientific reports

Publisher : National Library of Medicine

Source : Journal of Cancer Research and Therapeutics. 2023 Apr 4. DOI: 10.4103/jcrt.jcrt_2143_21

Url : https://pubmed.ncbi.nlm.nih.gov/37787288/

Campus : Kochi

School : School of Medicine

Year : 2023

Abstract : Ectopic production of amylase by tumor cells is known since 1951. Elevated amylase in multiple myeloma (MM) was first described in 1988. It has been postulated that translocation of chromosome 1, where amylase gene is situated, is responsible for ectopic production from the malignant plasma cells. Anecdotal reports have shown hyperamylasemia in MM to be associated with extensive bone disease, rapid progression, and shorter survival. Serum amylase estimation is a ubiquitous test. This prospective study was conducted to ascertain the degree of elevated amylase, its clinical utility, and implications in MM patients.

Cite this Research Publication : Panthula SV, Krishnan S, Jose WM. The utility of serum amylase as a prognostic marker in multiple myeloma. Journal of Cancer Research and Therapeutics. 2023 Apr 4. DOI: 10.4103/jcrt.jcrt_2143_21 (Ahead of Print)

Admissions Apply Now